suPAR与多发性骨髓瘤预后关系的研究进展  

Research Progress of Soluble Urokinase-type Plasminogen Activator Receptor and Prognosis of Multiple Myeloma

作　　者：黄艳平[1] 黄锦雄[1] 

机构地区：[1]广西柳州市人民医院血液科,广西柳州545006

出　　处：《医学综述》2013年第9期1584-1586,共3页Medical Recapitulate

基　　金：广西壮族自治区卫生厅自筹经费科研项目(Z-2012578)

摘　　要：尿激酶型纤溶酶原激活物与尿激酶型纤溶酶原激活物受体(uPAR)组成的纤溶系统调节纤溶酶原的活化过程,可参与细胞的黏附、转移及血管新生,可溶性尿激酶型纤溶酶原激活物受体是uPAR的可溶形式,缺乏糖基磷脂酰肌醇锚链结构,在肿瘤患者中高表达,有助于判断肿瘤患者的恶性程度及预后,为探讨肿瘤的治疗提供新途径。在多发性骨髓瘤中,其可通过参与骨基质的降解,刺激破骨细胞的增殖等发挥作用。Fibrinolysis system composed by the urokinase-type plasminogen activator and the urokinase- type plasminogen activator recptor （uPAR） regulates the active process of plasminogen, participates in cell adhesion, migration and neovasculization, soluble urokinase-type plasminogen activator receptor is a soluble form of uPAR, lack of glycosyl-phosphatidylinositol anchor domain, which is highly expressed in malignant tumors, and is helpful to distinguish the grade of malignancy and prognosis, and provide some new paths for the treatment. In multiple myeloma, uPAR participates in bone matrix degradation, timulates the proliferation of osteoclasts and so on.

关 键 词：可溶性尿激酶型纤溶酶原激活物受体 多发性骨髓瘤 预后 

分 类 号：R733.3[医药卫生—肿瘤]